 Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on harnessing the bodys immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Conejo-Garcia, Chair of the Department of Immunology at Moffitt Cancer Center, Anixas development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program. 